• Latest
  • Trending
Russia’s Sputnik V Vaccine is 91.6% Effective Against Symptomatic Covid-19, Trial Results Suggest

Russia’s Sputnik V Vaccine is 91.6% Effective Against Symptomatic Covid-19, Trial Results Suggest

February 2, 2021
Former France President Sarkozy Found Guilty of Corruption, Sentenced to Prison

Former France President Sarkozy Found Guilty of Corruption, Sentenced to Prison

March 1, 2021

Morning Show

March 1, 2021
Ramaphosa to Address South Africans on Covid 

South Africa Drops Coronavirus Alert Level After Dip in New Infections 

March 1, 2021
Nigeria, Kenya, 24 Other African Nations Set to Receive Covid Vaccines through COVAX

Nigeria, Kenya, 24 Other African Nations Set to Receive Covid Vaccines through COVAX

March 1, 2021
Germany Manufacturing PMI Revised Slightly Higher

Germany Manufacturing PMI Revised Slightly Higher

March 1, 2021
Ngozi Okonjo-Iweala Starts as WTO DG Today

Ngozi Okonjo-Iweala Starts as WTO DG Today

March 1, 2021
Dangote: Nigeria to Become Africa’s Largest Exporter of Cement, Fertilizer

Dangote: Nigeria to Save $2.5bn Annually from Petrochemical, Fertiliser Plants

March 1, 2021
As Fuel Queues Return, Nigeria’s State-owned Oil Company Cautions Against Panic Buying

As Fuel Queues Return, Nigeria’s State-owned Oil Company Cautions Against Panic Buying

March 1, 2021
Israel Ratifies Visa Exemption Agreement with UAE, the First with an Arab State

Netanyahu Says Iran ‘Clearly’ Behind Blast on Israeli-owned Ship

March 1, 2021
Katsina Schoolboys’ Kidnapping: Insecurity Prompts Nearby Zamfara State to Shut Schools 

Nigeria: Zamfara Governor Matawalle Insists on Negotiating with Bandits

March 1, 2021
Pope Prays for Abducted Zamfara Schoolgirls as Nigeria’s Military Intensifies Search

Pope Prays for Abducted Zamfara Schoolgirls as Nigeria’s Military Intensifies Search

March 1, 2021
Global Backlash Grows after Myanmar Forces Kill Two Protesters

Myanmar Protesters March Again Despite 18 Killed on Sunday

March 1, 2021
Trump to Address Major Meeting of Conservatives in First Post-White House Appearance

Trump Rules Out Forming New Political Party, Hints at Presidential Run in 2024

March 1, 2021
Liverpool End Run of Four League Defeats With Victory Over Sheffield United

Liverpool End Run of Four League Defeats With Victory Over Sheffield United

March 1, 2021
Chelsea 0-0 Man United: Blues Miss Top Four Chance With Goalless Draw

Chelsea 0-0 Man United: Blues Miss Top Four Chance With Goalless Draw

March 1, 2021
ARISE Newsnight

ARISE Newsnight

February 28, 2021
Dialogue with Bandits Very Relevant, Says Nigerian Governor

Zamfara Schoolgirls Yet to Be Rescued, Governor Matawalle Says

February 28, 2021
Nigeria’s Drug Agency Nabs Transborder Trafficker with Cocaine Worth $2.4m in Sokoto

Nigeria’s Drug Agency Nabs Transborder Trafficker with Cocaine Worth $2.4m in Sokoto

February 28, 2021
Leicester 1-3 Arsenal: Willian, Pepe Impress in Away Win 

Leicester 1-3 Arsenal: Willian, Pepe Impress in Away Win 

February 28, 2021
Is Sephora Making the Right Decision Expanding in 2021?

Is Sephora Making the Right Decision Expanding in 2021?

February 28, 2021
ARISE NEWSDAY

ARISE NEWSDAY

February 28, 2021
Morning Show

Morning Show

February 28, 2021
Two Reported Dead, Many Hurt as Myanmar Police Fire at Protesters

Two Reported Dead, Many Hurt as Myanmar Police Fire at Protesters

February 28, 2021
How Kagara Schoolboys, Others were Released

How Kagara Schoolboys, Others were Released

February 28, 2021
Popular Nigerian Music Producer Dr Frabz Reportedly Shot Dead in the US   

Popular Nigerian Music Producer Dr Frabz Reportedly Shot Dead in the US  

February 28, 2021

Released Kagara Schoolboys Went Through ‘Tremendous Torture’ in Captivity, Niger Governor Bello Says

February 28, 2021
Buhari ‘Disgusted’ By CNN, BBC Coverage of #EndSARS Protests

Buhari Tells Nigerian School Owners to Scale Up Security    

February 28, 2021
Nigeria: Northern Leaders Call for Prosecution of Criminal Herdsmen

Nigeria Government No Longer Able to Protect Nigerians, Says Northern Elders Forum    

February 28, 2021
US Calls on African Union to Exert Pressure Over Worsening Crisis in Ethiopia’s Tigray

US Calls on African Union to Exert Pressure Over Worsening Crisis in Ethiopia’s Tigray

February 28, 2021
Second Former Aide Accuses Cuomo of Sexual Harassment

Second Former Aide Accuses Cuomo of Sexual Harassment

February 28, 2021
en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianpt Portugueseru Russianes Spanish
No Result
View All Result
Monday, March 1, 2021
Arise News
  • HOME
  • Breaking
  • Global
  • Regional
  • BUSINESS
  • Politics
    • US ELECTION
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates
Arise News
  • HOME
  • Breaking
  • Global
  • Regional
  • BUSINESS
  • Politics
    • US ELECTION
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates
No Result
View All Result
Arise News
No Result
View All Result
Home Featured

Russia’s Sputnik V Vaccine is 91.6% Effective Against Symptomatic Covid-19, Trial Results Suggest

February 2, 2021
Reading Time: 5min
0 0
0
Russia’s Sputnik V Vaccine is 91.6% Effective Against Symptomatic Covid-19, Trial Results Suggest
Share on FacebookShare on Twitter

After criticism last year for an early rollout, Russia’s Sputnik V vaccine is 91.6% effective against symptomatic Covid-19 and 100% effective against severe and moderate disease, according to an interim analysis of the vaccine’s Phase 3 trial results.

Experts said the Phase 3 trial results meant the world had another effective weapon to fight the deadly pandemic and justified to some extent Moscow’s decision to roll out the vaccine before final data had been released.

The results, collated by the Gamaleya Institute in Moscow that developed and tested the vaccine, were in line with efficacy data reported at earlier stages of the trial, which has been running in Moscow since September.

“The development of the Sputnik V vaccine has been criticised for unseemly haste, corner cutting, and an absence of transparency,” said Ian Jones, professor at the University of Reading, and Polly Roy, professor at the London School of Hygiene & Tropical Medicine.

“But the outcome reported here is clear and the scientific principle of vaccination is demonstrated,” the scientists, who were not involved in the study, said in a comment shared by The Lancet. “Another vaccine can now join the fight to reduce the incidence of COVID-19.”

The results were based on data from 19,866 volunteers, of whom a quarter received a placebo, the researchers, led by the Gamaleya Institute’s Denis Logunov, said in The Lancet.

Since the trial began in Moscow, there were 16 recorded cases of symptomatic COVID-19 among people who received the vaccine, and 62 among the placebo group, the scientists said.

This showed that a two-dose regimen of the vaccine – two shots based on two different viral vectors, administered 21 days apart – was 91.6% effective against symptomatic COVID-19.

The Sputnik V vaccine is the fourth worldwide to have Phase III results published in leading peer-reviewed medical journals following the shots developed by Pfizer and BioNTech, Moderna and AstraZeneca.

Pfizer’s shot had the highest efficacy rate at 95%, closely followed by Moderna’s vaccine and Sputnik V while AstraZeneca’s vaccine had an average efficacy of 70%.

Sputnik V has also now been approved for storage in normal fridges, as opposed to freezers, making transportation and distribution easier, Gamaleya scientists said on Tuesday.

Russia approved the vaccine in August, before the large-scale trial had begun, saying it was the first country to do so for a COVID-19 shot. It named it Sputnik V, in homage to the world’s first satellite, launched by the Soviet Union.

Small numbers of frontline health workers began receiving it soon after and a large-scale roll out started in December, though access was limited to those in specific professions, such as teachers, medical workers and journalists.

In January, the vaccine was offered to all Russians.

“Russia was right all along,” Kirill Dmitriev, head of the Russian Direct Investment Fund (RDIF), which is responsible for marketing the vaccine abroad, told reporters on Tuesday.

Russia has already shared data from its Phase III trial with regulators in several countries and has begun the process of submitting it to the European Medicines Agency (EMA) for approval in the European Union, Dmitriev said.

The data release comes as Europe scrambles to secure enough shots for its 450 million citizens due to production cuts by AstraZeneca and Pfizer. The US roll-out, meanwhile, has been hampered by the need to store shots in ultra-cold freezers and uneven planning across states.

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2020 Arise News - Part of the Arise Media Group.

No Result
View All Result
  • HOME
  • Breaking
  • Global
  • Regional
  • BUSINESS
  • Politics
    • US ELECTION
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates

© 2020 Arise News - Part of the Arise Media Group.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist